In-Silico Studies of ELOC, SELENOS, UBB, TTYH2, AND MSRB3 Proteins Involved In Renal Cell Carcinoma

Renal cell carcinoma (RCC) is among the most aggressive kidney cancers, often diagnosed at advanced stages and associated with poor therapeutic outcomes. This study mainly focuses on five presently reported RCC-associated proteins: Elongin C (ELOC), Selenoprotein S (SELENOS), Polyubiquitin B precursor (UBB), Tweety homolog 2 (TTYH2), and Methionine-R-sulfoxide reductase B3 (MSRB3). The protein sequences from both NCBI and UniProt were downloaded, blasted for similarity searches, and multiple sequence alignments were performed to determine the alignments. SWISS-MODEL was used to build homology models of the proteins, which were validated using SAVES v6.1 and ProSA. Ligand binding pockets were predicted using CASTp, followed by docking with tyrosine kinase inhibitors (Axitinib, Pazopanib, Sunitinib, and Tivozanib) conducted in PyRx. Splitting of ligands was done by using AutoDock Vina to get the most suitable ligand conformation, and was visualized as well as analyzed by Discovery Studio. Docking results demonstrated effective binding, supported by stabilizing interactions. The types of bonds observed include conventional hydrogen bonds, hydrophobic interactions (alkyl, pi-alkyl, pi-sigma, pi-pi stacked, van der Waals), and electrostatic interactions such as pi-donor hydrogen bonds, pi-cation, and pi-anion contacts. These interactions confirmed the structural reliability of the protein models and their ability to form stable complexes with the tested inhibitors. In silico analysis confirmed that the selected proteins (ELOC, SELENOS, UBB, TTYH2, and MSRB3) are structurally reliable and exhibit stable interactions with tyrosine kinase inhibitors (Axitinib, Pazopanib, Sunitinib, and Tivozanib). These findings highlight their potential involvement in ccRCC progression and therapeutic response, supporting the role of computational protein–drug interaction studies in guiding personalized treatment strategies for renal cell carcinoma.